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Debate continues regarding the nosological status of binge eating disorder 
(BED) and the specific diagnostic criteria, including whether, like anorexia 
nervosa and bulimia nervosa, it should be characterized by body image 
disturbances in addition to abnormal eating behaviour. The aims of this article are: 
a) to concisely review the main points of the literature that has developed on 
diagnosis and treatment (especially pharmacological) of BED and b) to present the 
results of an original research on body image in obese patients with BED. The 
study was aimed to verify the following hypothesis: in persons with obesity, BED 
is associated with greater body uneasiness independently of some possible 
modulating factors. We studied a clinical sample of 159 (89 females and 70 males) 
adult obese patients who fulfilled DSM-IV-TR diagnostic criteria for BED 
matched to 159 non-BED obese patients for gender, ethnicity, BMI class, age, 
weight, stature, onset age of obesity, education level, and marital status. We used 
the Body Uneasiness Test (BUT), a valuable multidimensional tool for the clinical 
assessment of body uneasiness in subjects suffering from eating disorders and/or 
obesity. Obese patients with BED reported higher scores than non-BED patients in 
the General Severity Index (BUT-A GSI) and in every BUT-A subscale. All 
differences were statistically significant in both sexes. As expected women 
obtained higher scores than men. According to some other studies, our findings 
suggest that a negative body image should be included among diagnostic criteria 
for BED. Consequently, treatment should be focused not simply on eating 
behaviour and outcome studies should evaluate changes of body image as well. 
 
Keywords: binge eating disorder, obesity, body image, Body Uneasiness Test, 
drug treatment 
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INTRODUCTION 
 
Binge eating - objective overeating accompanied by the subjective experience 
of loss of control over eating - is a symptom that crosses the entire field of eating 
disorders (ED) and the whole spectrum of body weights: skeleton-like individuals, 
normal-weight subjects, and obese people may describe a similar, conflictual, 
craving for food (Fairburn & Wilson, 1993; Russell, 1997). On the other hand, 
binge eating disorder (BED) is the name of a syndrome that was formally 
recognized as a possible new diagnostic category in the fourth edition of the 
Diagnostic and Statistical Manual of Mental Disorders, DSM-IV (American 
Psychiatric Association, 1994). 
The first description of recurrent compulsive overeating as a clinical 
phenomenon probably dates back to 1932 (Stunkard, 1990; Wulff, 1932, 2001). 
In the following six decades, a winding path led to the proposal that BED 
should be added to the current crowded list of mental disorders (Cuzzolaro & 
Vetrone, in press). We might point out four milestones: 
i. Half a century ago, Albert Stunkard proposed the name of binge-eating 
syndrome for an eating pattern associated with obesity. We remind that an 
obese patient, Hyman Cohen, to name irresistible urges to overeat, coined the 
expression binge eating: "I didn’t enjoy it at all. It just happened. It is as a part 
of me just blacked out. And when that happened there was nothing there, 
except the food and me, all alone" (Stunkard, 1959). 
ii. In 1979, Gerald Russell named bulimia nervosa (BN) a syndrome that he 
considered "an ominous variant" of anorexia nervosa (AN) (Russell, 1979). 
People with BN suffer from frequent binge eating attacks, regular 
compensatory behaviours (self-induced vomiting and/or laxative abuse, and/or 
dieting, and/or excessive physical exercise), and morbid fear of fatness. Most 
of them maintain their weight within the normal range. 
iii. In the last decades of the past century clinicians increasingly reported on 
women and men who, like Stunkard’s patient, engaged in recurrent binge 
eating with marked distress but without the regular compensatory behaviours 
that characterize BN; most of these patients were obese. Based on these 
observations Spitzer and colleagues advanced the proposal of binge eating 
disorder (BED) as a new diagnostic category (Spitzer, 1991; Spitzer, Devlin, 
Walsh, Hasin, Wing, Marcus et al., 1992; Spitzer, Yanovski, Wadden, Wing, 
Marcus, Stunkard et al., 1993). 
iv. In 1994, DSM-IV agreed with Spitzer et al’s suggestion and recognized BED 
as a possible new diagnostic category. 
In the DSM-IV and in the DSM-IV-TR (American Psychiatric Association, 
2000) BED is proposed as an example of the eating disorder not otherwise 
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specified (EDNOS) category. Besides, it is included in Appendix B (possible new 
diagnostic categories requiring further study). BED is defined as follows: 
"recurrent episodes of binge eating in the absence of the regular use of 
inappropriate compensatory behaviours characteristic of bulimia nervosa". No 
equivalent diagnostic category exists in the ICD-10, the tenth edition of the WHO 
International Classification of Diseases (World Health Organization, 1992). The 
ICD-10 diagnosis for people who present the clinical picture of BED may be 
Atypical bulimia nervosa (code number F50.3) or Eating Disorder, unspecified 
(code number F50.9; WHO, 1993). 
Overall, BED is not yet a diagnosis approved in either DSM or ICD but it is the 
most distinct subgroup in the diagnostic category of EDNOS and an increasing 
number of scientific articles have been devoted to it. Although the conceptual 
issues of BED haven’t yet met sufficient agreement, BED is already accepted as an 
eating disorder (ED) in actual practice (Basdevant & Guy-Grand, 2004; Fairburn & 
Brownell, 2002; Goldstein, 2005; Grilo, 2006; Mitchell, Devlin, de Zwaan, Crow, 
& Peterson, 2008; Wadden & Stunkard, 2002). What is more, the new diagnostic 
category of BED has connected the psychiatric field of ED with the medical area of 
obesity: "The bridge drew more attention to the psychological and psychiatric 
aspects of obesity and gave a contribution to the development of a 
multidimensional team approach to the assessment and treatment of eating and 
weight disorders" (Cuzzolaro & Vetrone, in press). 
The purpose of this article is twofold: first, to concisely go over the main points 
of the literature that has developed on the nosological status of BED over the last 
fifteen years; and second, to present the results of an original research aimed to 
study body image uneasiness in a clinical sample of 159 (females 89 and males 70) 
adult obese patients who fulfilled DSM-IV-TR diagnostic criteria for BED. 
 
BED: nosological status and diagnostic criteria 
 
The nosological status of BED has not yet met adequate accord. In 1999, 
Williamson and Martin reviewed the first five years of research on BED and 
concluded that questions about the definition of BED persisted: this cluster 
symptom presentation may be conceptualized as a separate psychiatric syndrome or 
it may be viewed as a frequent behavioural symptom associated with obesity 
(Williamson & Martin, 1999). 
Stunkard, the researcher who originally described binge eating, in a thought-
provoking article, wrote that the great variability of BED limits the implications 
that can be drawn from its diagnosis and, in particular, the presence or absence of 
BED is not a useful distinction in selecting treatment for obese individuals: BED 
may be more useful as "a marker of psychopathology" than as new distinct 
diagnostic entity (Stunkard & Allison, 2003). 
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Some years later, Walsh and Satir reviewed the literature published during the 
period 2002-2003 and concluded that "a consensus does not yet appear to have 
formed in the field regarding the wisdom of formally designating BED as an eating 
disorder" (Walsh & Satir, 2005). In contrast, Dingemans et al., discussing the 
empirical status of BED after a decade of research, concluded, "There is evidence 
to suggest that BED represents a distinct eating disorder category" (p. 76) 
(Dingemans, van Hanswijck de Jonge, & van Furth, 2005). In 2007, Wilfley et al. 
supported the same point of view: BED should be made an official diagnostic 
category in DSM-V (Wilfley, Bishop, Wilson, & Agras, 2007). In addition, some 
authors investigated the question of whether the current classifications of ED 
capture the natural clustering of eating-related pathology: should ED be 
conceptualized as discrete syndromes or as dimensions that differ in degree among 
individuals? 
Williamson and colleagues explored the latent structure of ED symptoms, as 
defined by DSM-IV, and using taxometric analyses found empirical support for 
conceptualizing BN and BED as discrete syndromes (Williamson, Womble, 
Smeets, Netemeyer, Thaw, Kutlesic et al., 2002). 
As regards diagnosis of BED, the Eating Disorders Work Group of the DSM-
IV task force in conjunction with Spitzer and colleagues (1992) developed the 
provisional diagnostic criteria for BED along three lines: 
 the person suffers from recurrent episodes of binge eating (the binge eating 
occurs, on average, at least two days a week for six months), 
 the binge eating is not associated with the regular use of inappropriate 
compensatory behaviours, 
 marked distress regarding binge eating is present. 
In the last decade, several authors have raised doubts about the DSM-IV 
research criteria for BED (Cuzzolaro & Vetrone, in press). Firstly, difficulties with 
diagnosis may arise from the precise recognition of binge eating episodes in obese 
persons (Wilfley, Schwartz, Spurrell, & Fairburn, 2000). The distinction between 
binge eating (irresistible acute attack) and compulsive grazing (urge to eat without 
a complete loss of control that may last an entire day) may be arduous. In the 
second place, a number of researchers found that the boundary line between full-
syndrome BED and partial or sub-threshold BED (STBED) is unclear (Crow, 
Agras, Halmi, Mitchell, & Kraemer, 2002; Striegel-Moore, Dohm, Solomon, 
Fairburn, Pike, & Wilfley, 2000). Wilfley and colleagues included among their 
recommendations for DSM-V "unifying the frequency and duration cut-points for 
BN and BED to once per week for 3 months" (Wilfley et al., 2007). Next, distress 
as an emotional state should be distinguished from distress as impairment in social 
or occupational functioning (Dingemans et al., 2005). Then, obesity is not a current 
criterion for the diagnosis of BED but perhaps it should be included in the same 
way as underweight is a criterion for the diagnosis of AN. This problem is still 
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unresolved (Dingemans et al., 2005). Finally, unlike the two major eating disorders 
(ED) - anorexia nervosa (AN) and bulimia nervosa (BN) - BED does not include a 
body image disturbance among the DSM-IV provisional diagnostic criteria. Should 
body image disturbance be added to the diagnostic criteria for BED? 
 
BED and negative body image 
 
Schilder originally characterized body image as "the picture of our own body 
which we form in our mind, that is to say the way in which the body appears to 
ourselves" (Schilder, 1935). In fact, body image is a multidimensional 
psychological construct, which includes perceptual, cognitive, emotional, 
relational, and behavioural components (Pruzinsky & Cash, 2002). Rosen has 
coined the expression negative body image (Rosen, 1998, 2002) to include all cases 
of clinically significant uneasiness due to body image in subjects with objective 
anomalies concerning appearance (e.g. people with obesity) and in subjects with 
basically imaginary or exaggerated, or at times both, aesthetic problems (e.g. 
people with body dysmorphic disorder, AN or BN). 
The first systematic studies on body image in subjects with obesity date back to 
the 1960’s (Stunkard & Burt, 1967; Stunkard & Mendelson, 1967) and their 
clinical relevance has continued to increase in the years. The obesity galaxy is 
enormous and heterogeneous: it is well known that such factors as gender, age, 
degree of obesity, onset age of overweight, ethnicity, social class, history of 
childhood teasing and parental criticism about weight, history of weight cycling, 
and presence of binge eating all show important modulating effects on body 
uneasiness (Sarwer & Thompson, 2002; Sarwer, Thompson, & Cash, 2005; 
Schwartz & Brownell, 2002). 
It is well known that there are essential links between ED and body image 
disturbances (Habermas, 1989), at least in Western countries (Dorian & Garfinkel, 
2002), from the beginning of the twentieth-century (Janet, 1903; Wulff, 2001). 
However, unlike AN and BN, current diagnostic criteria for BED focus completely 
on eating behaviour and feelings about binge eating and do not include body image 
distortion and/or distress. In the last fifteen years, several studies have remarked 
that obese individuals with BED present greater dissatisfaction and distress about 
their body appearance than obese people without BED. 
Wilfley et al. (2000) found that patients with BED had weight and shape 
concerns comparable to BN patients and higher than AN patients and concluded 
that their results "supported the status of BED as an eating disorder and suggest that 
the elevated Eating Disorder Examination scores reflect the combined impact of 
being objectively overweight and having disordered cognitions and behaviours 
about eating, shape, and weight". The Eating Disorder Examination (EDE) is a 
semistructured interview useful in assessment and diagnosis of eating disorders 
(Fairburn & Cooper, 1993). 
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Reas et al. (2005) studied repetitive body checking (e.g. pinching some body 
areas to check for fatness) and avoidance behaviours (e.g. avoiding close-fitting 
clothes) in 377 (80 men and 297 women) overweight (BMI ≥ 25) treatment-seeking 
BED patients. Significant associations emerged between checking and restraint, 
and conversely, between avoidance and binge eating (Reas, Grilo, Masheb, & 
Wilson, 2005). Hrabosky et al. (2007) found that in 399 patients with BED, 
shape/weight overvaluation was unrelated to BMI but was strongly associated with 
psychometric measures of eating-related psychopathology and psychological 
functioning (higher depression and lower self-esteem). They suggested that 
shape/weight overvaluation "warrants consideration as a diagnostic feature for 
BED" (Hrabosky, Masheb, White, & Grilo, 2007). One year later Grilo et al. found 
that overweight BED patients who overvalue their shape/weight reported greater 
eating-related psychopathology and depression levels than overweight BED 
patients do with subclinical levels of overvaluation. Nevertheless, both BED groups 
reported greater overall eating pathology and depression levels than the overweight 
non-BED comparison group (Grilo, Hrabosky, White, Allison, Stunkard, & 
Masheb, 2008). There are gender differences. Reas and colleagues remarked that 
obese women with BED reported significantly greater levels of body checking than 
obese men with BED (Reas et al., 2005). Guerdjikova et al. compared 44 obese 
males with BED with 44 age- and race-matched obese females with BED seeking 
weight loss treatment. They found that males had fewer previous attempts at weight 
loss or less help-seeking behaviour, possibly related to their less pronounced body 
dissatisfaction (Guerdjikova, McElroy, Kotwal, & Keck, 2007). 
As regards general psychiatric comorbidity, it is linked with increased severity 
of ED symptoms; in general, there are associations between specific ED symptoms 
and specific forms of comorbidity (Spindler & Milos, 2007). Fernandez-Aranda et 
al. recently studied a sample of women with ED and found that impulse control 
disorders (e.g. compulsive buying disorder, kleptomania) occurred more in 
individuals with binge eating subtypes, and were associated, in particular, with 
greater body image disturbance (Fernandez-Aranda, Pinheiro, Thornton, Berrettini, 
Crow, Fichter et al., 2008). 
 
Is BED an indication or a contraindication for specific treatments? 
Can drugs relieve BED and weight/shape concerns? 
 
The validity of the diagnosis of BED as a discrete syndrome depends largely on 
the answers to these questions. For clinicians treating obese patients in a weight 
control program, a crucial unresolved question is whether individuals with BED 
benefit from specialized interventions (surgical, pharmacological, or psychosocial) 
in addition to standard behavioural weight control treatment. As regards obesity 
surgery, more than a few studies suggest that a diagnosis of BED or a history of 
binge eating prior to treatment may be associated with unsatisfactory weight loss in 
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obese patients submitted to bariatric procedures (Mitchell & de Zwaan, 2005; 
Sallet, Sallet, Dixon, Collis, Pisani, Levy et al., 2007). 
Patients presenting with both obesity and BED face multiple challenges: 
promoting and maintaining weight loss, normalizing their eating patterns, 
improving their physical and psychological health, and working to enhance their 
own acceptance of their body image. Several psychological and pharmacologic 
treatment approaches have been used in this population. Most suppress binge eating 
in the short term, and some seem promising in the long term as well. However, 
sustained weight loss remains a largely unrealized goal. A particular question is 
whether the diagnosis of BED is an indication for specific pharmacological 
treatments.  
In the last two decades, BED has been studied intensely as target for 
pharmacotherapy. Table 1 makes a list of 24 double-blind placebo-controlled trials. 
 
Table 1. Drug treatment of binge eating disorder: double-blind placebo-controlled 














(McCann & Agras, 1990) desipramine 23 12 ≤ 300 d > p ns 
(Marcus et al., 1990) fluoxetine 21 52 60 ns d > p 







d > p 
d > p 
(Stunkard et al., 1996) d-fenfluramine 28 8 30 d > p ns 
(Hudson et al., 1998) fluvoxamine 85 9 50-300 d > p d > p 
(Laederach-Hofmann et al., 
1999) 
imipramine 31 8 75 d > p d > p 
(McElroy et al., 2000) sertraline 34 6 50-200 d > p d > p 
(Arnold et al., 2002) fluoxetine 60 6 20-80 d > p d > p 
(McElroy et al., 2003a) topiramate 61 14 25-600 d > p d > p 
(Pearlstein et al., 2003) fluvoxamine 20 12 239 ns ns 
(Appolinario et al., 2003) sibutramine 60 12 15 d > p d > p 
(McElroy et al., 2003b) citalopram 38 6 20-60 d > p d > p 
(Grilo et al., 2005b) fluoxetine 108 16 up to 60 ns ns 
(Devlin et al., 2005) fluoxetine 116 20 up to 60 ns ns 
(Milano et al., 2005) sibutramine 20 12 10 d > p d > p 
(Golay et al., 2005) orlistat 89 24 360 ns d > p 
(Grilo et al., 2005a) orlistat 50 12 360 ns d > p 
(McElroy et al., 2006) zonisamide 60 16 100-600 d > p d > p 
(Bauer et al., 2006) sibutramine 73 16 15 ns d > p 
(McElroy et al., 2007b) topiramate 407 16 25-400 d > p d > p 
(McElroy et al., 2007a) atomoxetine 40 10 40-120 d > p d > p 
(Claudino et al., 2007) topiramate 73 21 200 d > p d > p 
(Guerdjikova et al., 2008) escitalopram 44 12 26.5 ? d > p 
(Wilfley et al., 2008) sibutramine 304 24 15 d > p d > p 
Note. d > p = drug superior to placebo; ns = not significant difference 
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Research is still in its preliminary stages but a number of drugs have shown 
evidence of some therapeutic value in BED and according to several researchers 
pharmacotherapy may be a useful component of a multidimensional treatment 
approach. The medication dosage is usually at the high end of the recommended 
range. Some studies have examined the added benefit of drugs and psychosocial 
interventions. 
Fluoxetine, an antidepressant of the selective serotonin reuptake inhibitor 
(SSRI) class was the first drug to receive an indication for treatment of bulimia 
nervosa and was tested in several trials for BED, often associated with cognitive 
behavioural therapy (CBT). In a double-blind placebo-controlled trial of fluoxetine 
plus behaviour modification in the treatment of obese binge-eaters and non-binge-
eaters, Marcus et al. found that patients treated with fluoxetine (60 mg/day) plus 
behaviour modification lost significantly more weight than those treated with 
placebo plus behaviour modification (Marcus, Wing, Ewing, Kern, McDermott, & 
Gooding, 1990). However, the drug did not appear to have a differential benefit for 
binge-eaters. 
Grilo et al. (2005b) obtained partly dissimilar results when they compared 
fluoxetine (60 mg/day), placebo, CBT+fluoxetine and CBT+placebo in a sample of 
108 patients with BED (Grilo, Masheb, & Wilson, 2005b). Remission rates (zero 
binges for 28 days) for completers were 29% (fluoxetine), 30% (placebo), 55% 
(CBT+fluoxetine), and 73% (CBT+placebo). Weight loss was modest and did not 
differ across treatments. The authors concluded that CBT, but not fluoxetine, 
demonstrated efficacy for the behavioural and psychological features of BED, but 
not for obesity. 
Molinari et al. (2005) compared CBT, fluoxetine and CBT+fluoxetine: the two 
groups which underwent psychotherapy resulted in a better outcome after 12 
months - in terms of number of bingeing episodes, weight loss and psychological 
well being - than the group treated with pharmacological therapy alone; 
furthermore, the drug did not appear to add a significant benefit to CBT (Molinari, 
Baruffi, Croci, Marchi, & Petroni, 2005). This investigation was not placebo-
controlled. 
Devlin et al. (2005) studied 116 overweight/obese women and men with BED 
receiving a 16-session standard group behavioural weight control treatment over 20 
weeks (Devlin, Goldfein, Petkova, Jiang, Raizman, Wolk et al., 2005). 
Simultaneously, subjects were randomly assigned to receive CBT+fluoxetine, 
CBT+placebo, fluoxetine, or placebo in a two-by-two factorial design. This 
interesting study was designed to examine the added benefit of two adjunctive 
interventions, individual CBT, and fluoxetine, offered in the context of standard 
group treatment. In general, patients showed substantial improvement in binge 
eating but little weight loss. Subjects who received also individual CBT improved 
more in binge frequency while fluoxetine treatment was associated with greater 
reduction in depressive symptoms. Two years later Devlin et al. (2007) followed up 
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the same patients and found that CBT was still associated with lower binge 
frequency and fluoxetine with a significant advantage on depressive symptoms: 
short-term (5-month) treatment may provide long-term (24-month) benefit (Devlin, 
Goldfein, Petkova, Liu, & Walsh, 2007). 
In other studies, on the contrary, success seemed to be very short-lived. 
Stunkard et al. (1996) conducted an 8-week controlled clinical trial of the appetite 
suppressant d-fenfluramine with 28 severely obese female patients meeting full 
criteria for BED (Stunkard, Berkowitz, Tanrikut, Reiss, & Young, 1996). They 
found that the rate of binge eating in the d-fenfluramine group fell three times more 
rapidly than that in the placebo group but at 4-month follow-up, the binge 
frequency had increased to pre-treatment levels and no longer differed from that of 
the placebo group. Furthermore, surprisingly, in this trial the appetite suppressant d-
fenfluramine was not associated with significant weight loss. Some years ago, this 
drug has been withdrawn from the market due to adverse cardiovascular effects, 
specifically valvular heart disease. 
In Hudson and colleagues’ study fluvoxamine, a SSRI antidepressant drug, was 
found effective as well in the acute treatment of BED (reduction in the frequency of 
binges) (Hudson, McElroy, Raymond, Crow, Keck, Carter et al., 1998). We 
highlight three other results of this trial. First, there was no significant difference 
between placebo and fluvoxamine groups in the rate of decrease in Hamilton 
depression scale scores. Next, the placebo response rate was very high: 44% of the 
patients given placebo displayed a greater than 50% reduction in binges/week; in 
passing, even higher placebo response rates have been observed in other studies of 
BED and these figures prove that this disorder may often improve even with 
placebo. Finally, compared with placebo, fluvoxamine was associated with a 
significantly greater rate of reduction in BMI.  
McElroy et al.’s investigations showed that two other SSRI antidepressant 
drugs, sertraline (McElroy, Casuto, Nelson, Lake, Soutullo, Keck et al., 2000) and 
citalopram (McElroy, Hudson, Malhotra, Welge, Nelson, & Keck et al., 2003b) 
were also associated with significantly greater rates of reduction in binges/week and 
BMI than placebo. Leombruni et al. (2007) did not find significant differences 
between sertraline (dose range: 100-200mg/day) and fluoxetine (dose range: 40-80 
mg/day) in a randomized, double-blind, 24-weeks trial in obese patients with BED: 
a significant improvement in the Binge Eating Scale score and a significant weight 
loss emerged (Leombruni, Piero, Dosio, Novelli, Abbate-Daga, Morino et al., 
2007). Both reboxetine (Silveira, Zanatto, Appolinario, & Kapczinski, 2005), a 
selective noradrenalin reuptake inhibitor, and venlafaxine (Malhotra, King, Welge, 
Brusman-Lovins, & McElroy, 2002), antidepressant of the serotonin-
norepinephrine reuptake inhibitor (SNRI) class, appeared to be effective and well-
tolerated agents for the treatment of BED in non-controlled studies. Reboxetine was 
also associated with a statistically significant decrease in BMI. 
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Evidence suggests (Tata & Kockler, 2006) that topiramate, an anticonvulsant 
drug, may have mood-stabilizing properties, and cause decreased appetite and 
weight. Two studies described the short- and long-term efficacy of topiramate for 
BED associated with obesity. The short-term study (McElroy, Arnold, Shapira, 
Keck, Rosenthal, Karim et al., 2003a) was a 14-week, single-center, randomized, 
double blind, placebo-controlled trial; compared with placebo, topiramate was 
associated with a significantly greater rate of reduction in binge frequency and 
BMI. Subsequently, the long-term study (McElroy, Shapira, Arnold, Keck, 
Rosenthal, Wu et al., 2004) - a 42-week, open-label extension trial - showed 
enduring improvement in a number of patients with BED and obesity but was also 
associated with a high discontinuation rate. Topiramate was titrated from 25 
mg/day to a maximum of 600 mg/day (median final dose of 250 mg/day). Adverse 
reactions included paresthesias, cognitive impairment, somnolence, headache, 
nausea, and gastrointestinal distress. These adverse effects are transient but they 
may interfere with patients' tolerability of topiramate therapy. 
In 2007, a 16-week, multicenter, study (McElroy, Hudson, Capece, Beyers, 
Fisher, & Rosenthal, 2007b) in a large sample of 407 obese patients with BED (age 
18-65) confirmed that topiramate was well tolerated and efficacious in improving 
the features of BED and in reducing body weight. In particular, topiramate induced 
binge eating remission in 58% of patients (placebo in 29%; p < .001). A flexible-
dose investigation started at 25 mg/day and was titrated weekly over an 8-week 
period to 400 mg/day or the maximum tolerated dose. Discontinuation rates were 
high (about 30%) in each group. According to Guerdjikova et al, anecdotal 
observations, topiramate may be an effective treatment also for patients with BED 
and obesity who experience recurrent binge eating and weight gain after initially 
successful bariatric surgery (Guerdjikova, Kotwal, & McElroy, 2005). 
Zonisamide is another antiepileptic drug associated with weight loss that 
appears to be a promising candidate for selective use in the treatment of 
overweight/obesity (Appolinario, Bueno, & Coutinho, 2004). McElroy et al. (2006) 
evaluated this anticonvulsant drug in 60 obese outpatients with BED (McElroy, 
Kotwal, Guerdjikova, Welge, Nelson, Lake et al., 2006). Compared with placebo, 
zonisamide was associated with a significantly greater rate of reduction in binge 
eating episode frequency, body weight, and Three Factor Eating Questionnaire 
Disinhibition Scale score (Stunkard & Messick, 1985). Eight patients receiving 
zonisamide discontinued because of adverse events. The authors concluded that 
zonisamide was efficacious, but not well tolerated, in the short-term treatment of 
BED. At this time, only three products have been approved for treatment of 
obesity: sibutramine, orlistat and rimonabant (in Europe and Canada), a 
cannabinoid type 1-receptor blocker. 
Sibutramine and orlistat have been studied in patients with BED: both 
sibutramine and orlistat promote weight loss in obese patients with BED but only 
sibutramine may reduce the frequency of binge eating and the intensity of related 
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depressive symptoms Sibutramine is a serotonin and norepinephrine reuptake 
inhibitor. An important double-blind study by Appolinario et al. (2003) evaluated 
its efficacy and tolerability in 60 obese patients with BED (Appolinario, 
Bacaltchuk, Sichieri, Claudino, Godoy-Matos, Morgan et al., 2003). The 
researchers found a significant reduction in the number of days with binge episodes 
in the sibutramine group compared with the placebo group; this was associated 
with a significant weight loss (-7.4 kg) compared with a small weight gain in the 
placebo group (1.4 kg). Sibutramine was also associated with a significantly greater 
rate of reduction in Binge Eating Scale (BES; Gormally, Black, Daston, & Rardin, 
1982) and Beck Depression Inventory scores (BDI; Beck, Ward, Mendelson, 
Mock, & Erbaugh, 1961). 
There was a significant reduction in the number of days with binge episodes in 
the sibutramine group compared with the placebo group, this was associated with 
an important and significant weight loss (-7.4 kg) compared with a small weight 
gain in the placebo group (1.4 kg). Milano et al. (2005) used a smaller dose of 
sibutramine (10 mg/day) and, after 12 weeks, found that the binge frequency 
among patients who received sibutramine was significantly lower than that among 
those who received placebo (Milano, Petrella, Casella, Capasso, Carrino, & 
Milano, 2005). In 2008 (Wilfley et al., 2008), the first large-scale, multisite, 
placebo-controlled trial confirmed the efficacy of sibutramine (15 mg) in reducing 
binge eating, weight (sibutramine group mean = - 4.3kg [SD = 4.8], placebo group 
mean = - 0.8kg [SD = 3.5]), and associated psychopathology (Yager, 2008). 
Bauer et al. (2006) recently assessed the effect of sibutramine and cognitive-
behavioural weight loss (CBWL) treatment in obese subjects with and without 
subthreshold binge eating disorder (sBED). Treatment with CBWL programs and 
sibutramine leads to a higher weight loss than CBWL + placebo. Subjects with 
sBED significantly reduced their binge episodes during treatment, but with no 
augmenting effect of sibutramine (Bauer, Fischer, & Keller, 2006). 
Orlistat is a gastrointestinal lipase inhibitor that exerts its activity in the lumen 
of the stomach and small intestine and promotes weight loss through the partial 
(30%) inhibition of dietary fat absorption. A number of investigators demonstrated 
the efficacy and safety of orlistat but they excluded patients with BED. Golay et al. 
(2005) hypothesized that orlistat may be considered as part of the management of 
overweight/obesity also for patients with BED. They randomized in double-blind 
fashion 89 obese patients with BED to treatment with orlistat or placebo in 
combination with a mildly reduced-calorie diet (Golay, Laurent-Jaccard, Habicht, 
Gachoud, Chabloz, Kammer, et al. 2005). After 24 weeks, the orlistat-group 
showed a mean weight loss from baseline significantly greater than the placebo 
group. However, patients in both treatment groups showed a comparable decrease 
in the mean number of reported binge eating episodes (and duration of episodes) 
per week. At the end of the study, orlistat-treated patients were less likely to have a 
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diagnosis of BED than placebo-treated patients were but this difference did not 
reach statistical significance. 
In another randomized, placebo-controlled study, Grilo et al. (2005a) added 
orlistat (120 mg three times a day) to guided self-help CBT (CBTgsh) to treat 50 
obese patients with BED (Grilo, Masheb, & Salant, 2005a). The addition of orlistat 
was associated with greater weight loss than the addition of placebo. Like in Golay 
et al.’s study, the authors found in both groups significant but similar improvements 
in eating disorder psychopathology and psychological distress. Both sibutramine 
and orlistat promote weight loss in obese patients with BED but only sibutramine 
reduces the frequency of binge eating and the intensity of related depressive 
symptoms (Appolinario et al., 2003). 
Novel pharmacological interventions are needed and many compounds may be 
promising and/or are in early phases of clinical testing (Steffen, Roerig, Mitchell, & 
Uppala, 2006). For example, Broft et al. (2007) recently studied, in a small open-
label trial, baclofen, a GABA-B agonist that may be useful the treatment of 
substance use disorders, and also reduces binge-like eating in rodents (Broft, 
Spanos, Corwin, Mayer, Steinglass, Devlin et al., 2007). Baclofen (60 mg/day) was 
associated with decreased binge eating frequency in patients with BED and BN. 
Atomoxetine is a highly selective norepinephrine reuptake inhibitor associated with 
weight loss. It was originally intended to be a new antidepressant drug and was the 
first non-stimulant drug approved for the treatment of attention-deficit hyperactivity 
disorder (ADHD). McElroy et al evaluated atomoxetine in the treatment of BED in 
a 10-week, randomized, double-blind, placebo-controlled, flexible dose (40-120 
mg/day) trial. Compared with placebo, atomoxetine (N = 20) was associated with a 
significantly greater rate of reduction in binge-eating frequency, BMI, and Three 
Factor Eating Questionnaire hunger subscale (Stunkard & Messick, 1985). The 
drug was fairly well tolerated. 
It is hoped that in a near future the development of genetic researches in the 
field of ED will probably "help the clinician to choose the most appropriate 
treatment, using genetic polymorphisms of vulnerability genes, those linked to 
endophenotypes, or genes implicated in the metabolism of the drug treatment" 
(Ramoz, Versini, & Gorwood, 2007). To sum up, at present, several medications 
may contain binge eating, at least in the short term, but weight loss is small or 
absent. Furthermore, most trials were very brief and, in particular, did not study 
body image and weight and shape concerns at baseline, endpoint, and follow-up. 
 
An observational study 
 
In this section we present the results of an observational (empirical comparison 
of groups) cross-sectional (data were collected from subjects at a single time) study 
on body image in obese patients with and without BED. 
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We studied a sample of 159 (males 70 and females 89) adult (mean age of 
males: 35.77±10.17; mean age of females: 36.93±11.62) subjects with obesity 
(Body Mass Index, BMI ≥ 30 kg/m2) and BED (DSM-IV-TR), drawn from 3 581 
outpatients who came to lose weight to three medical centres, accredited by the 
Italian Health Service for the treatment of obesity, from 2005 to 2007. 
We recruited all the male patients (70) who fulfilled the DSM-IV-TR 
provisional criteria for BED and 89 consecutive female patients. Then we matched 
them to 159 non-BED obese patients (males 70 and females 89) drawn from the 
same population. Each O-BED subject was matched exactly to one control for 
gender, ethnicity (all Caucasian), and BMI class (Class I = 30-34.9; Class II = 35-
39.9; Class III ≥ 40) looking for the best compromise for six other matching 
variables: age, weight, stature, onset age of obesity, education level, and marital 




Weight and Height 
 
A physician measured each patient’s weight on a medical-balance and height 




We used the Body Uneasiness Test (BUT), a valuable multidimensional tool 
for the clinical assessment of body uneasiness in subjects suffering from eating 
disorders (Cuzzolaro, Vetrone, Marano, & Battacchi, 2000; Cuzzolaro, Vetrone, 
Marano, & Garfinkel, 2006; Ravaldi, Vannacci, Bolognesi, Mancini, Faravelli, & 
Ricca, 2006) and/or obesity (Carano, De Berardis, Gambi, Di Paolo, Campanella, 
Pelusi et al., 2006; Dalle Grave, Cuzzolaro, Calugi, Tomasi, Temperilli, & 
Marchesini, 2007; Marano, Cuzzolaro, Vetrone, Garfinkel, Temperilli, Spera et al., 
2007). The BUT is a self-administered questionnaire that consists of two parts: 
BUT-A (34 items) and BUT-B (37 items). Higher scores indicate greater body 
uneasiness. The BUT was specifically designed to explore several areas in clinical 
and non-clinical populations: 
 BUT-A: body shape/weight dissatisfaction, avoidance, compulsive control 
behaviours, detachment and estrangement feelings towards one’s own 
body (examples of items: I avoid mirrors; If I begin to look at myself, I find 
it difficult to stop; I have the sensation that my body does not belong to me) 
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 BUT-B: specific worries about particular body parts, shapes, or functions 
(examples of items: the shape of my face; buttocks; odour; blushing). 
In keeping with the previous validation studies the BUT-A scores were 
combined in a Global Severity Index (GSI, 34 items) and in 5 subscales resulting 
from factorial analysis: Weight Phobia (WP - fear of being or becoming fat, 8 
items), Body Image Concerns (BIC - worries related to physical appearance, 9 
items), Avoidance (A - body image-related avoidance behaviour, 6 items), 
Compulsive Self-Monitoring (CSM - compulsive checking of physical appearance, 
5 items), and Depersonalization (D - detachment and estrangement feelings toward 
the body, 6 items); BUT-B scores were combined in two global measures (Positive 
Symptom Total – PST and Positive Symptom Distress Index – PSDI) and in eight 
factors that examine specific worries about particular sets of body parts or 
functions. 
The levels of Cronbach’s alpha coefficients range between .64 and .89. All the 
subscales but one (BUT-B VII, a factor that contains only two items) showed 
Cronbach’s alpha coefficients greater than .70 (Cuzzolaro et al., 2006; Marano et 
al., 2007). Therefore, internal consistency of BUT appears good (Nunnally, 1978; 
Thompson, Penner, & Altabe, 1990). For the present study, we considered only the 
BUT-A scores.  
The English version of the BUT and scoring instructions are reported in the 
validation studies (Cuzzolaro et al., 2006; Marano et al., 2007).1 The test was 
administered in a self-reported fashion (i.e., the investigators did not assist the 
subjects in the compilation of the questionnaire). The diagnosis of BED was 
formulated based on the semi-structured diagnostic interview, EDE 12.0D 
(Fairburn & Cooper, 1993). The ethical committees of the individual centres 
approved the protocol of this multicenter study. All participants gave written 




We used chi-square statistics for categorical dependent variables and t-test for 
quantitative dependent variables. The analyses were performed using JMP 6.0.3 




Table 2 shows means and standard deviations of age, weight, stature, and BMI 
of the different subgroups. Comparing the BED patients with the non-BED patients 
of the same sex (t-test) no statistically significant difference was found at the .05 
alpha level. 
                                                 
1 The Italian and the French versions of the test are available from the authors on request. 
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Table 2. Matching variables: age, weight, height and Body Mass Index 
 
Males   Females     
BED 
N = 70 
NON–BED
N = 70 
t 
BED 
N = 89 
NON–BED
N = 89 
t 
M 35.77 36.24 0.26 36.93 36.90 0.02 
Age (years) 
SD 10.17 9.67  11.62 11.52  
M 141.39 141.78 0.09 109.73 110.24 0.20 
Weight (kg) 
SD 27.41 23.52  17.10 17.35  
M 1.76 1.78 1.37 1.63 1.63 0.72 
Height (m) 
SD 0.07 0.07  0.06 0.07  
M 45.40 44.73 0.51 41.49 41.35 0.16 
BMI (kg/m²) 
SD 7.63 6.92  5.69 6.01  
BED – Binge Eating Disorder 
 
Figure 1 illustrates the onset age of obesity (percentages) of the subgroups. 
Comparing the BED patients with the non-BED patients of the same sex (chi-
square test) no statistically significant difference was found at the .05 alpha level 
(chi-square: 0.43 for males and 0.00 for females). 
 



























years 18 < 
years 18 ≥ 
 
Table 3 shows the education level and the marital status of the subgroups. 
Comparing the BED patients with the non-BED patients of the same sex (chi-
square test) no statistically significant difference was found at the .05 alpha level. 
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Table 3. Matching variables: education level and marital status 
 
Males  Females    
BED NON–BED   X2 BED NON–BED X2 
Elementary school (≤ 5 years) 4% 6% 0.71 10% 8% 0.28 
Middle school (8 years) 37% 44% 0.54 33% 36% 0.23 










University degree 10% 10% 0 8% 4% 0.88 
Single 57% 49% 0.81 40% 40% 0.00 
Married 33% 37% 0.32 54% 51% 0.20 








Widowed     0 0 0 2% 1% 0.35 
 
BED – Binge Eating Disorder 
 
Table 4 shows the BUT-A scores (means and standard deviations) of the 
different subgroups. Patients with BED reported significantly (t-test) higher scores 
than non-BED patients in the General Severity Index (BUT-A-GSI) and in every 
subscale of the BUT-A. 
 
Table 4. Means and standard deviations of body uneasiness scores in binge eating 
disordered and non-binge eating disordered obese patients 
 
Males  Females  
BUT-A scores BED 
N = 70 
NON-BED
N = 70 
t 
BED 
N = 89 
NON–BED 
N = 89 
t 
M 2.11 1.33 2.83 1.97 
Global Severity Index 
SD 1.07 0.93 
4.32*** 
 0.98 1.19 
5.22*** 
 
M 2.57 1.73 3.17 2.45 
Weight Phobia 
SD 1.22 1.08 
4.04*** 
 1.13 1.36 
3.84** 
 
M 3.02 2.06 3.71 2.79 
Body Image Concerns 
SD 1.43 1.44 
3.72** 
 1.10 1.44 
4.78*** 
 
M 1.68 0.76 2.66 1.47 
Avoidance 
SD 1.32 0.85 
4.63*** 
 1.28 1.33 
6.12*** 
 
M 0.95 0.67 1.47 1.11 
Compulsive Self Monitoring 
SD 0.87 0.64 
2.03* 
 1.06 1.04 
2.29* 
 
M 1.48 0.79 2.32 1.32 
Depersonalization 
SD 1.19 0.89 
3.65** 
 1.26 1.30 
5.23*** 
 
*p < .05     **p < .01     ***p < .001 
BUT-A – Body Uneasiness Test; BED – Binge Eating Disorder 
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DISCUSSION 
 
Several investigations found that subjects with BED appear very similar to 
those with AN or BN in terms of their overvalued ideas regarding weight and 
shape. In clinical as well as community samples, persons suffering from BED 
reported significantly greater levels of body dissatisfaction and weight/shape 
concerns compared to non-BED subjects; this correlation is not explained by the 
degree of depression (Barry, Grilo, & Masheb, 2003; Masheb & Grilo, 2000; 
Mussell, Mitchell, de Zwaan, Crosby, Seim, & Crow, 1996a; Mussell, Peterson, 
Weller, Crosby, de Zwaan, & Mitchell, 1996b; Striegel-Moore, Cachelin, Dohm, 
Pike, Wilfley, & Fairburn, 2001). 
It is well known that such factors as gender, age, onset age of overweight, 
degree of obesity, ethnicity, social class, all show important modulating effects on 
body image disturbances in obese persons (Marano et al., 2007; Sarwer & 
Thompson, 2002; Sarwer et al., 2005; Schwartz & Brownell, 2002). 
The empirical investigation we have described in this article was an 
observational study aimed to verify the following hypothesis: in persons with 
obesity, BED is associated with greater body uneasiness independently of some 
possible modulating factors. 
In planning our research, we have tried to remove some biases by matching, 
that is the most direct and intuitive method of adjustment for overt (those that have 
been accurately measured) biases: matching compares each individual to one 
control who appears comparable in terms of observed covariates (Rosenbaum, 
2005). 
In our study, each BED subject was matched exactly to one non-BED control 
for gender, ethnicity (all Caucasian), and BMI class looking for the best 
compromise for some other variables: when the recruitment was completed, we did 
not find significant differences for these variables between BED and non-BED 
subgroups. 
To assess body image disturbance we used the self-report questionnaire BUT. 
We have chosen this test because it is a valuable multidimensional instrument that 
was developed with the specific aim of investigating not only body dissatisfaction, 
but also other dimensions of so-called negative body image: body shape and/or 
weight dissatisfaction, body image-related avoidance behaviours, compulsive body 
checking behaviours, detachment and estrangement feelings towards one’s own 
body, specific worries about particular body parts, shapes or functions (Cuzzolaro 
et al., 2006). In addition, the BUT was recently validated in Italy in a very large 
sample of subjects with obesity (Marano et al., 2007). 
Obese patients with BED reported higher scores than non-BED patients in the 
General Severity Index (BUT-GSI) and in every subscale of the BUT-A. All 
differences were highly significant except one: in the Compulsive Self-Monitoring 
subscale (CSM) BED patients obtained scores higher than non-BED controls but p 
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was only < .05 in both sexes. Finally and unsurprisingly, obese women with BED 
reported higher scores than obese men with BED in the BUT-A-GSI and in every 
subscale of the BUT-A. We can find a parallel result in Reas et al.’s study (2005): 
obese women with BED reported significantly greater levels of body checking than 




The first limitation of this study is the absence of a general population sample 
of obese subjects with BED and without BED. Next, the absence of clinical and 
general population samples of non-obese (BMI < 30) subjects with BED. Finally, it 
could be useful to compare the BUT scores with those obtained by using other 
body image assessment tools or a diagnostic semi-structured interview, such as 
Body Dysmorphic Disorder Evaluation, BDDE (Cuzzolaro & Aveni, 2000; Rosen 
& Reiter, 1996). 
 
Clinical implications and future research directions 
 
In accordance with a number of other studies (Hrabosky & Grilo, 2007; 
Masheb & Grilo, 2000) our findings suggest that a negative body image should be 
included among diagnostic criteria for BED. A negative body image could also 
drive obese binge eaters to seek bariatric surgery more often than non-BED obese 
subjects, other conditions being equal. Colles, Dixon, & O'Brien (2008) wrote that 
loss of control is central to psychological disturbance associated with BED and 
suggested that "feelings of loss of control could drive binge eaters to seek bariatric 
surgery in an attempt to gain control over body weight and psychologically 
disturbing eating behaviour".  
In conclusion, assessment and treatment of persons with obesity and BED 
should consider cognitive as well as behavioural dysfunctional attitudes and 
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